Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.
Authors
Richard Francis Dunne
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Richard Francis Dunne , Nicholas A. Ullman , Brian A. Belt , Luis I. Ruffolo , Paul Burchard , Aram F Hezel , Jason Zittel , Wenjia Wang , Erika E. Ramsdale , Vivek Kaul , John Zebala , David Linehan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04477343
DOI
10.1200/JCO.2022.40.4_suppl.TPS631
Abstract #
TPS631
Poster Bd #
Q7
Abstract Disclosures
Similar Posters
First Author: Igor Tsaur
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.
First Author: Eric Christenson
Poster
2022 ASCO Annual Meeting
Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.
First Author: Haeseong Park
Poster
2022 ASCO Annual Meeting
STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Benny Johnson